IIPR · Innovative Industrial Properties, Inc.

Innovative Industrial Properties reported Q1 2026 results reflecting resilience amid tenant challenges, with total revenues of $69.0 million slightly below prior year due to $6.9 million impact from defaults at tenants like PharmaCann and Gold Flora, partially offset by contractual escalations, new leasing revenue, and a February 2025 acquisition. Net income to common stockholders was stable at $30.2 million ($1.02 diluted EPS), while AFFO of $53.4 million ($1.88/share) declined modestly from $1.94/share YoY, maintaining a 101% payout ratio on the $1.90 quarterly dividend. Management highlighted strong leasing momentum, executing nearly 400,000 square feet YTD including full-building leases to Gramlin (two California properties totaling 260,000 sq ft) and Grown Rogue (Illinois), plus a post-quarter Curaleaf deal in Ohio, driving operating portfolio occupancy to 97.8%. Tenant resolutions progressed: PharmaCann litigation settled with property turnover by late May 2026 and $3.0 million payments received YTD; Gold Flora properties re-leased; 4Front backfill arrangements tentative pending receivership. Balance sheet strengthened via $128 million YTD capital raises ($70.9 million preferred, $34.9 million common ATM proceeds), boosting cash to $89.1 million and liquidity to $176.6 million at 13% gross leverage. IQHQ life sciences commitment advanced to $150 million funded ($100 million revolver, $50 million preferred), plus $25 million post-quarter, targeting diversification from 93% cannabis exposure. G&A rose to 15% of revenues from litigation ($1.9 million expense), but interest income surged $4.7 million YoY from IQHQ yields. With $291 million Notes due 2026 maturing soon, ongoing $130 million debt refinancings and note repurchases position for growth in triple-net leased industrial assets across 19 states.